Sydnexis

Sydnexis is a privately held biopharmaceutical company focused on advancing care for pediatric progressive myopia (PPM)—a serious condition that affects millions of children and can lead to long-term vision complications. Our proprietary low-dose atropine formulation, SYD-101, is designed to slow the progression of myopia and help protect lifelong visual health. SYD-101 is approved in the European Union and will be commercialized as Ryjunea® by our exclusive regional partner, Santen. In the United States, SYD-101 recently completed its pivotal three-year Phase 3 clinical trial and is now in the final year of the randomized withdrawal phase. Headquartered in San Diego and backed by leading life sciences investors, Sydnexis is committed to changing the trajectory of childhood vision through science-driven innovation.